Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | WebDisclosure

Basculer en Français

8718	Companies
152882	Keywords
88474	Articles
82173	Press releases

Headlines Articles Press releases Protagonist Therapeutics, Inc.

Home
Companies
Protagonist Therapeutics, Inc.

BRIEF

published on 01/30/2025 at 00:20, 4 months 18 days ago

Protagonist Therapeutics annonce un événement destiné aux investisseurs axé sur la polycythémie vraie et le rusfertide

Essais Cliniques Rusfertide Thérapeutique Protagoniste Événement Pour Les Investisseurs Polycythémie Vraie
BRIEF

published on 01/30/2025 at 00:20, 4 months 18 days ago

Protagonist Therapeutics Announces Investor Event Focused on Polycythemia Vera and Rusfertide

Clinical Trials Investor Event Protagonist Therapeutics Rusfertide Polycythemia Vera
PRESS RELEASE

published on 01/30/2025 at 00:15, 4 months 18 days ago

Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025
Protagonist Therapeutics to host investor event discussing Rusfertide Phase 3 VERIFY study design and Phase 2 data with key opinion leaders. Company also to provide commercial opportunity snapshot. Live Q&A session and lunch included

Investor Event Protagonist Therapeutics Rusfertide Phase 3 VERIFY Study Commercial Opportunity
BRIEF

published on 01/06/2025 at 22:10, 5 months 10 days ago

Protagonist Therapeutics annonce des primes d'encouragement à un nouveau dirigeant

Nasdaq Thérapeutique Protagoniste Options Sur Actions Primes D'encouragement Nouveau Comité Exécutif
BRIEF

published on 01/06/2025 at 22:10, 5 months 10 days ago

Protagonist Therapeutics Announces Inducement Awards to New Executive

Stock Options Nasdaq Protagonist Therapeutics Inducement Awards New Executive
PRESS RELEASE

published on 01/06/2025 at 22:05, 5 months 10 days ago

Protagonist Therapeutics Reports Granting of Inducement Awards
Protagonist Therapeutics grants inducement awards to Dr. Newman Yeilding for the role of Executive Vice President, Chief Scientific Officer, under inducement plan. Company's focus on peptide therapeutics and Phase 3 drug development

Protagonist Therapeutics Phase 3 Clinical Development Inducement Awards Peptide Therapeutics Drug Candidates
BRIEF

published on 12/19/2024 at 22:10, 5 months 28 days ago

Protagonist Therapeutics présentera ses produits à la conférence JP Morgan Healthcare

Rusfertide Thérapeutique Protagoniste Icotrokinra Développement Biopharmaceutique Conférence De JP Morgan
BRIEF

published on 12/19/2024 at 22:10, 5 months 28 days ago

Protagonist Therapeutics to Present at J.P. Morgan Healthcare Conference

Protagonist Therapeutics Rusfertide Icotrokinra Biopharmaceutical Development J.P. Morgan Conference
PRESS RELEASE

published on 12/19/2024 at 22:05, 5 months 28 days ago

Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
Protagonist Therapeutics to present company overview at 43rd Annual J.P. Morgan Healthcare Conference. Highlights late-stage peptides in clinical development

Clinical Development Biopharmaceutical Protagonist Therapeutics J.P. Morgan Healthcare Conference Peptides
BRIEF

published on 12/09/2024 at 22:10, 6 months 7 days ago

Protagonist Therapeutics révèle des résultats prometteurs pour son étude sur le rusfertide à l'ASH 2024

Rusfertide Polycythémie Vraie Phase 2 REVIVE ASH 2024 Contrôle De L'hématocrite

Accesswire

Published on 06/17/2025 at 00:35, 35 minutes ago

Nepra Foods Announces Non-Brokered Private Placement
Published on 06/17/2025 at 00:18, 52 minutes ago

From Generic to Verticalized: Amdocs Unveils a Standard for Skilled, Trustworthy Telco-Grade AI Agents
Published on 06/16/2025 at 23:00, 2 hours 10 minutes ago

GECC Announces Urban Design Panel Approval for the GEC Langara Project with Increased Density
Published on 06/16/2025 at 23:00, 2 hours 10 minutes ago

Star Gold Corp. to Present at the Emerging Growth Conference on June 18, 2025
Published on 06/16/2025 at 23:00, 2 hours 10 minutes ago

Guanajuato Silver Confirms Terms of Warrant Expiry

View all ACCESSWIRE

EQS Group

Published on 06/16/2025 at 22:00, 3 hours 10 minutes ago

Saudia Arabia Introduces Strategic Healthcare Vision and Global Partnerships at BIO 2025
Published on 06/16/2025 at 20:04, 5 hours 6 minutes ago

EQS-Adhoc: The Grounds Real Estate Development AG: Management Board negotiating potential takeover of asset management for individual companies of the insolvent Ziegert Group -
Published on 06/16/2025 at 19:50, 5 hours 20 minutes ago

Netfonds AG publishes audited annual financial statements for 2024 / Proposal to increase dividend by 40% to EUR 0.35 per share
Published on 06/16/2025 at 19:40, 5 hours 30 minutes ago

Mukuru Named FXC Intelligence Top 100 Cross-Border Payments Company for Sixth Year
Published on 06/16/2025 at 19:01, 6 hours 8 minutes ago

Mister Spex SE stays on strategic course despite market headwinds: EBIT guidance confirmed, revenue guidance adjusted

Les Echos

Published on 06/16/2025 at 19:09, 6 hours ago

250616 BENETEAU Transactions sur actions propres
Published on 06/16/2025 at 18:00, 7 hours 10 minutes ago

Covivio reprend la pleine propriété de la tour CB21 dans un contexte dynamique pour le marché de Paris-La Défense
Published on 06/16/2025 at 18:00, 7 hours 10 minutes ago

Covivio takes over full ownership of the CB21 tower in a dynamic context for Paris-La Défense market
Published on 06/16/2025 at 18:00, 7 hours 10 minutes ago

Mr.Bricolage lance deux tests sur la distribution de marques propres de Kingfisher et la conversion d’un magasin Mr.Bricolage en franchise Brico Dépôt.
Published on 06/16/2025 at 18:00, 7 hours 10 minutes ago

Mr.Bricolage launches two pilot initiatives: the distribution of Kingfisherowned brands and the conversion of a Mr.Bricolage store into a Brico Dépôt franchise.

View all LES ECHOS COMFI WIRE